Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q3 FY25 results · Oct–Dec 2024
Bliss GVS Pharma reported revenue from operations of ₹210.42 crore (up 4.8% from Q3 FY24) and net profit of ₹25.80 crore (down 11.2% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 210.42 | 200.72 | +4.8% | 217.68 | −3.3% |
| Other income | 15.27 | 5.42 | +181.5% | 5.04 | +203.0% |
| Total income | 225.68 | 206.14 | +9.5% | 222.72 | +1.3% |
| Profit before tax | 36.42 | 40.04 | −9.1% | 35.71 | +2.0% |
| Net profit for the period | 25.80 | 29.07 | −11.2% | 25.69 | +0.4% |
| Attributable to shareholders of the company | 23.80 | 27.61 | −13.8% | 24.26 | −1.9% |
| EPS, basic (₹) | 2.27 | 2.64 | −14.0% | 2.31 | −1.7% |
| Net margin (%) | 12.3 | 14.5 | 11.8 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 179.59 | 161.33 | +11.3% | 182.65 | −1.7% |
| Other income | 11.66 | 7.90 | +47.7% | 8.35 | +39.6% |
| Total income | 191.25 | 169.23 | +13.0% | 191.00 | +0.1% |
| Profit before tax | 29.77 | 28.52 | +4.4% | 23.89 | +24.6% |
| Net profit for the period | 21.05 | 20.72 | +1.6% | 17.04 | +23.5% |
| EPS, basic (₹) | 2.00 | 1.99 | +0.5% | 1.63 | +22.7% |
| Net margin (%) | 11.7 | 12.8 | 9.3 |
Consolidated
- Filed with BSE
- 29 Jan 2025, 17:13 IST
- Board meeting
- 28 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 Jan 2025, 17:13 IST
- Board meeting
- 28 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE